Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...
Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...
Shares of Sanofi and Regeneron both jumped by more than 6% on Thursday after the pharmaceutical companies released promising data showing their jointly developed asthma drug Dupixent also shows ...
Dupixent (dupilumab) is a prescription drug used to treat certain inflammatory conditions, such as asthma and atopic dermatitis. It’s not known whether Dupixent is safe to use while pregnant or ...
Regeneron Pharmaceuticals (NASDAQ:REGN) stock is on the rise Thursday after the company released its latest data on Dupixent. Dupixent is a drug candidate for treating adults on maximal ...
Sanofi SAN posted first-quarter results largely in line with our projections, and we don’t expect any major changes to the firm’s fair value estimate. The stock looks undervalued with the market not ...
By Bhanvi Satija and Mariam Sunny LONDON, April 23 (Reuters) - French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results